The hesitation of the National Institute for Health and Care Excellence (NICE) in sanctioning a “miracle” drug for Cystic Fibrosis, as recently reported in this paper, might seem harsh and unfair. Still the watchdog’s decision is certainly illustrative of an ever more pressing problem – the NHS simply can’t afford to pay the inflated prices charged by pharmaceutical companies for new medicines.